These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 16649327

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
    Breiterman-White R.
    Nephrol Nurs J; 2006; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C.
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Managing the anemia of end-stage renal disease after hospitalization.
    Krishnan M, Adams E.
    Nephrol Nurs J; 2004 Dec; 31(5):541-4. PubMed ID: 15518256
    [Abstract] [Full Text] [Related]

  • 7. C-reactive protein and anemia: implications for patients on dialysis.
    Breiterman-White R.
    Nephrol Nurs J; 2006 Dec; 33(5):555-8. PubMed ID: 17044439
    [Abstract] [Full Text] [Related]

  • 8. Tools for analyzing trends in anemia management case study of the anemic patient.
    Aiello J.
    Nephrol Nurs J; 2000 Feb; 27(1):57-60. PubMed ID: 10852692
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hyporesponse to Epoetin alfa: patients at risk. Case study of the anemic patient.
    Deziel SM.
    Nephrol Nurs J; 2002 Feb; 29(1):60-3. PubMed ID: 11887489
    [Abstract] [Full Text] [Related]

  • 11. Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient.
    Collins A, Ellefson J.
    Nephrol Nurs J; 2000 Apr; 27(2):233-6. PubMed ID: 11111551
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Assessing the impact of concomitant therapies on anemia in dialysis patients. Case study of the anemic patient.
    Gregory N.
    Nephrol Nurs J; 2000 Jun; 27(3):320-3; quiz 324-5. PubMed ID: 11249331
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R, Easom A, Juergensen P.
    Nephrol Nurs J; 2007 Mar; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS, Fishbane S, Elzein H, Lynn RI, Deoreo PB, Tharpe DL, Meisels IS.
    Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.